BerGenBio announces exclusive in-license of key intellectual property rights from UT Southwestern Medical Center
In-Licensing further strengthens intellectual property estate for the treatment of Non-Small Cell Cancer (NSCLC) patients with STK11 mutations Bergen, Norway, 16 December 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announced today the licensing of certain intellectual property from the UT Southwestern Medical Center. The exclusive license to intellectual property generated by researchers at UT Southwestern Medical Center supports the Company's existing IP position underlying use